Cancer name Triple Negative Breast Cancer
Cancer Type BLCA
Immunotherapy type Cancer Vaccine;Immune Checkpoint Therapy
Treatment P53MVA
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature Eomes
Official Symbol EOMES
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial Phase I
Description Numerous markers of successful T cell stimulation were elevated post treatment, including durable upregulation of T-bet(TBX21), Eomes, OX40(TNFRSF4), CXCR3, IFN-γ, CXCL10, and KLRG1.
PMID 29209571
Title Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab